{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:56:21Z","timestamp":1754484981924,"version":"3.41.2"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>SSc is a CTD characterized by excessive fibrosis of the skin and internal organs, along with microvascular damage, and is often associated with typical autoantibodies. The aim of this study was to analyse the correlation between specific autoantibody profiles, clinical and paraclinical features in Moroccan patients with SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed the presence of specific autoantibodies in 46 SSc patients using IIF on HEp-2 cells and immunodot. We then correlated the types of autoantibodies with clinical and laboratory manifestations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among our patients, 86.9% were females. The mean age of patients at diagnosis was 50.21\u2009years, with an average delay to diagnosis of 5\u2009years. The main clinical manifestations found were RP (89.2%), sclerodactyly (84.8%), proximal scleroderma (67.4%), gastrointestinal involvement (50%) and interstitial lung disease (30.4%). According to the specific autoantibody profile, 14 patients were anti-topo I positive (30.4%), 8 anti-RNP (68\u00a0kDa\/A\/C) positive (17.4%) and 6 anti-RNA polymerase III positive (13%). We found a significant association of anti-RNA polymerase III with sclerodactyly and pulmonary arterial hypertension (P\u2009&amp;lt;\u20090.05). We also found an association between anti-topo I and interstitial lung disease in 30.4% of patients. There was no significant association between the positivity for the autoantibodies and other diagnosed clinical manifestations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Some clinical manifestations of SSc might be positively correlated with the presence of specific autoantibodies. Environmental factors, ethnicity and gene interaction might also influence this correlation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkad036","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:55:18Z","timestamp":1680533718000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical and serological correlation of systemic sclerosis in Moroccan patients"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1659-6692","authenticated-orcid":false,"given":"Kaoutar","family":"Ouazahrou","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalila","family":"El Bakkouri","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"},{"name":"Immunology Laboratory, IbnRochd University Hospital Center , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0247-546X","authenticated-orcid":false,"given":"Manal","family":"Souali","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Jeddane","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaoula","family":"Mokhantar","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahmane","family":"Errami","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"El Kabli","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, IbnRochd University Hospital Center , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Aziz","family":"Bousfiha","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"},{"name":"Clinical Immunology Unit P1, IbnRochd University Hospital Center, Mother and Child El Harouchi Hospital , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khadija","family":"Echchilali","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology, Inflammation and Allergy, Faculty of Medicine and Pharmacy, Hassan II University , Casablanca, Morocco"},{"name":"Internal Medicine Department, IbnRochd University Hospital Center , Casablanca, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"2023041921384101700_rkad036-B1","first-page":"3","article-title":"One year in review 2018: systemic sclerosis","volume":"36(Suppl 113)","author":"Orlandi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2023041921384101700_rkad036-B2","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.jaci.2009.10.067","article-title":"Immunologic rheumatic disorders","volume":"125","author":"Joseph","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"2023041921384101700_rkad036-B3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2397198319870667","article-title":"Pathogenic roles of autoantibodies in systemic sclerosis: current understandings in pathogenesis","volume":"5","author":"Sen\u00e9cal","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2023041921384101700_rkad036-B4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5606\/ArchRheumatol.2018.6578","article-title":"Juvenile scleroderma: a referral center experience","volume":"33","author":"Adrovic","year":"2018","journal-title":"Arch Rheumatol"},{"key":"2023041921384101700_rkad036-B5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol"},{"key":"2023041921384101700_rkad036-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.55563\/clinexprheumatol\/izadb8","article-title":"One year in review 2021: systemic sclerosis","volume":"39(Suppl 131)","author":"Di Battista","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2023041921384101700_rkad036-B7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/kjm2.12505","article-title":"Pathophysiology of systemic sclerosis (scleroderma)","volume":"38","author":"Rosendahl","year":"2022","journal-title":"Kaohsiung J Med Sci"},{"key":"2023041921384101700_rkad036-B8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2023041921384101700_rkad036-B9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J Nippon Med Sch"},{"key":"2023041921384101700_rkad036-B10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"2023041921384101700_rkad036-B11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0889-857X(05)70297-0","article-title":"Antinuclear antibody in systemic sclerosis (scleroderma)","volume":"22","author":"Okano","year":"1996","journal-title":"Rheum Dis Clin North Am"},{"key":"2023041921384101700_rkad036-B12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2023041921384101700_rkad036-B13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.62.9.904","article-title":"European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score","volume":"62","author":"Valentini","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2023041921384101700_rkad036-B14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-8949-2_3","article-title":"Detection of autoantibodies by indirect immunofluorescence cytochemistry on HEp-2 cells","volume":"1901","author":"Dellavance","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2023041921384101700_rkad036-B15","first-page":"126","article-title":"Autoantibody profile in a cohort of Algerian patients with systemic sclerosis","volume":"78","author":"Tahiat","year":"2020","journal-title":"Ann Biol Clin (Paris)"},{"key":"2023041921384101700_rkad036-B16","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/j.lpm.2019.07.037","article-title":"Clinical and serological profile of systemic sclerosis in Tunisia: a retrospective observational study","volume":"48","author":"Ben Salah","year":"2019","journal-title":"Presse Med"},{"key":"2023041921384101700_rkad036-B17","first-page":"104","article-title":"Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis","volume":"34","author":"Meyer","year":"2007","journal-title":"J Rheumatol"},{"key":"2023041921384101700_rkad036-B18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.semarthrit.2011.10.004","article-title":"Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status","volume":"41","author":"Sime\u00f3n-Aznar","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"2023041921384101700_rkad036-B19","first-page":"S-94-7","article-title":"Systemic sclerosis in Argentina: evaluation of a large cohort from a single centre and comparison with other international series","volume":"32","author":"Scolnik","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2023041921384101700_rkad036-B20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"2023041921384101700_rkad036-B21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2023041921384101700_rkad036-B22","doi-asserted-by":"crossref","first-page":"e0214202","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"2023041921384101700_rkad036-B23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.rbr.2014.09.007","article-title":"Autoanticorpos em esclerose sist\u00eamica e sua correla\u00e7\u00e3o com as manifesta\u00e7\u00f5es cl\u00ednicas da doen\u00e7a em pacientes do Centro-Oeste do Brasil [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil]","volume":"55","author":"Coelho Horimoto","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"2023041921384101700_rkad036-B24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/08916934.2011.592886","article-title":"Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients","volume":"44","author":"Rodriguez-Reyna","year":"2011","journal-title":"Autoimmunity"},{"key":"2023041921384101700_rkad036-B25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2397198318786158","article-title":"Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: why and how to screen","volume":"3","author":"Lazzaroni","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"2023041921384101700_rkad036-B26","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case\u2013control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023041921384101700_rkad036-B27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0961203308089442","article-title":"Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases","volume":"17","author":"Cavazzana","year":"2008","journal-title":"Lupus"},{"key":"2023041921384101700_rkad036-B28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.revmed.2019.12.020","article-title":"Characteristics of Systemic Sclerosis patients with positive anti-Th\/To antibodies: about 6 patients and literature review","volume":"41","author":"Muller","year":"2020","journal-title":"Rev Med Interne"},{"key":"2023041921384101700_rkad036-B29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/23971983221074749","article-title":"Systemic sclerosis in Asians: are there racial differences?","volume":"7","author":"Ng","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"2023041921384101700_rkad036-B30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"2023041921384101700_rkad036-B31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2023041921384101700_rkad036-B32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/art.39432","article-title":"Characteristics and survival of Anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension","volume":"68","author":"Sobanski","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023041921384101700_rkad036-B33","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1212\/WNL.0000000000007188","article-title":"Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies","volume":"92","author":"Casal-Dominguez","year":"2019","journal-title":"Neurology"},{"key":"2023041921384101700_rkad036-B34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","article-title":"Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma \u2013 a review","volume":"17","author":"Nunes","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2023041921384101700_rkad036-B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2020.02.005","article-title":"Proteomics characterization of CENP-B epitope in Moroccan scleroderma patients with anti-centromere autoantibodies","volume":"221","author":"Zian","year":"2020","journal-title":"Immunol Lett"},{"key":"2023041921384101700_rkad036-B36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"key":"2023041921384101700_rkad036-B37","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"2023041921384101700_rkad036-B38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13075-015-0573-x","article-title":"Anti-PM\/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma","volume":"17","author":"Muro","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2023041921384101700_rkad036-B39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/sji.12510","article-title":"The clinical relevance of antifibrillarin (anti-U3-RNP) autoantibodies in systemic sclerosis","volume":"85","author":"Tall","year":"2017","journal-title":"Scand J Immunol"},{"key":"2023041921384101700_rkad036-B40","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"2023041921384101700_rkad036-B41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.humimm.2016.10.017","article-title":"Genomic and genetic studies of systemic sclerosis: a systematic review","volume":"78","author":"Chairta","year":"2017","journal-title":"Hum Immunol"},{"key":"2023041921384101700_rkad036-B42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/14397595.2018.1519148","article-title":"Human leukocyte antigen (HLA)-DRB1 allele polymorphisms and systemic sclerosis","volume":"29","author":"Xu","year":"2019","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkad036\/49732074\/rkad036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/2\/rkad036\/50035840\/rkad036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/2\/rkad036\/50035840\/rkad036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T21:39:16Z","timestamp":1681940356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkad036\/7100353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4,12]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkad036","relation":{},"ISSN":["2514-1775"],"issn-type":[{"type":"electronic","value":"2514-1775"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"rkad036"}}